ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
NYSE:ADCT
Price:
4.78 USD
-3.82%
Market Closed
Updated:
Apr 25, 2024
ADC Therapeutics SA
Cash from Operating Activities
Last
Value
3-Years CAGR
5-Years CAGR
|
ADC Therapeutics SA
Cash from Operating Activities Peer Comparison
Comparables:
ACIU
CRSP
BSLN
IDIA
KURN
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Cash from Operating Activities
-$118.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Cash from Operating Activities
-CHf60.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Cash from Operating Activities
-$260.4m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Cash from Operating Activities
CHf14.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Cash from Operating Activities
-CHf859.1m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Cash from Operating Activities
-CHf8.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Cash from Operating Activities?
Cash from Operating Activities
-118.7m
USD
-118.7m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Cash from Operating Activities amounts to -118.7m USD.
What is ADC Therapeutics SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
0%
0%
Over the last year, the Cash from Operating Activities growth was 13%. The average annual Cash from Operating Activities growth rates for ADC Therapeutics SA have been 11% over the past three years .
You don't have any saved screeners yet
